CD274 and lung carcinoma: PD-L1 is the key molecule of immune checkpoint pathway, making it a predictive biomarker for ICI treatment (29), and positive PD-L1 expression is associated with higher ICI response rates in both advanced and early lung cancer patients (30–32).